Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$42.91 ▲ +1.82
(+4.43%)
MKT CAP: $2.20B • VOL: 544.9K
52W L $29 52W H $49
VCEL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $276.3M | $237.2M | $197.5M |
| YoY Revenue Growth % | +16.5% | +20.1% | — |
| Gross Profit | $205.6M | $172.1M | — |
| Gross Margin % | 74.4% | 72.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $11.0M | $4.5M | -$6.5M |
| Operating Margin % | 4.0% | 1.9% | -3.3% |
| Net Income (GAAP) | $16.5M | $10.4M | -$3.2M |
| EBITDA (Normalized) | $32.8M | $55.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $51.9M | $58.2M | $35.3M |
| Capital Expenditures (CapEx) | $27.2M | $64.0M | — |
| Free Cash Flow (FCF) | $24.7M | -$5.8M | $35.3M |
| FCF Margin % | 9.0% | -2.4% | 17.9% |
| Return on Invested Capital (ROIC %) | 3.4% | 1.6% | — |
| Cash & Short-Term Equivalents | $100.1M | $74.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $354.6M | $292.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VCEL.